Related Experiment Video

Updated: Jun 3, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

"Combination-oriented molecular-targeting prevention" of cancer: a model involving the combination of TRAIL and a DR5

Tatsushi Yoshida1, Mano Horinaka, Toshiyuki Sakai

  • 1Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.

Environmental Health and Preventive Medicine
|March 25, 2011
PubMed

Insights

Combining chemopreventive agents targeting tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) offers a promising strategy for cancer prevention. This approach enhances apoptosis in malignant cells, potentially improving outcomes in cancer chemoprevention.

Area of Science:

  • Oncology
  • Preventive Medicine
  • Molecular Biology

Background:

  • Malignant tumors pose a significant mortality risk, making cancer prevention a critical area of research.
  • Single chemopreventive agents have shown limited efficacy, necessitating the exploration of combination therapies.
  • Developing guidelines for selecting effective agent combinations is essential for clinical application.

Purpose of the Study:

  • To propose a "combination-oriented molecular-targeting prevention" strategy for cancer.
  • To identify molecular targets and agents that can be effectively combined for enhanced chemoprevention.
  • To validate the synergistic effect of combined agents in inducing cancer cell apoptosis.

Main Methods:

  • Focused on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as a molecular target.
  • Investigated chemopreventive agents that up-regulate death receptor 5 (DR5) expression.
  • Evaluated the synergistic induction of apoptosis in malignant tumor cells when agents were combined with TRAIL.

Main Results:

  • Identified several chemopreventive agents that enhance the expression of TRAIL receptor, death receptor 5.
  • Demonstrated that combinations of these agents synergistically induce apoptosis in malignant tumor cells.
  • Showcased the potential of targeting TRAIL pathways for enhanced cancer prevention.

Conclusions:

  • "Combination-oriented molecular-targeting prevention" is a practical strategy for cancer chemoprevention.
  • Targeting TRAIL and its receptors offers a viable approach for synergistic cancer cell death induction.
  • This strategy provides a framework for developing more effective cancer prevention therapies.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...